Navigation Links
Optimer Pharmaceuticals' Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
Date:8/19/2010

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the European Medicines Agency (EMA) has accepted for review Optimer's Marketing Authorization Application (MAA) for fidaxomicin for the treatment of patients with Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI in the European Union (EU).  Optimer announced the submission of its MAA for fidaxomicin to the EMA on August 2, 2010.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"An independent survey recently conducted by Decision Resources indicates that CDI is on the rise and that nearly 70% of surveyed infectious disease specialists and internists would use fidaxomicin in first- and second-line treatment of CDI, if approved," said Pedro Lichtinger, President and CEO of Optimer. "We believe the potential demand for a narrow spectrum antibiotic with lower recurrence rates for the treatment of CDI is significant. The acceptance for review of the fidaxomicin marketing application by the EMA is an important step in bringing this much needed therapy to Europe, where treatment options are limited.  With the validation of this MAA, we believe we have significantly improved the risk profile of our European program that when combined with our growing excitement and understanding of CDI incidence, access and prescribing intentions across the region, present an enhanced value proposition for fidaxomicin."  

Given these developments, the Company is increasing its focus on its European partnering process for fidaxomicin. J.P. Morgan has been engaged to advise and assist Optime
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Global ENT (Ear, Nose, And ... 23.01 million in 2022, according to a new study ... population, increasing prevalence of ear, nose, and throat related ... target customer base are expected serve this market as ... to estimates published by the WHO, 15% of adult ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud ... predictive analytics technology, announces it is working with ... solutions for the new Lockheed Martin Healthcare Technology ... leading health information technology providers, medical technology companies ... collaboration and innovation to improve care in rapidly ...
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
Breaking Medicine Technology:ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 13, 2007 -,Cytos Biotechnology AG (SWX:CYTN) reported ... with CYT003-QbG10, an immunotherapeutic,product candidate for the ... patients suffering from mild to moderate allergic,rhinitis ... The trial,investigated in a doubleblind setting the ...
... company Pharmaxis today announced the results,from its Phase ... Pulmonary Disease (COPD), a respiratory disease,affecting over 30 ... in 79 diagnosed COPD patients at 12,centres in ... to,determine if subjects that were positive to an ...
Cached Medicine Technology:Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4
(Date:7/31/2015)... Nashville, TN (PRWEB) , ... July 31, 2015 ... ... Nashville, Tenn. has launched a Balloon Sinuplasty website to inform potential Nashville ... includes a questionnaire that can be used to determine if someone is a ...
(Date:7/30/2015)... ... July 30, 2015 , ... Dale Sky Jones, Executive Chancellor of Oaksterdam ... International Cannabis Professionals Expo held at the Caribe Royal All Suites Hotel and Convention ... Expo is the largest medical cannabis expo in the country and this year’s ...
(Date:7/30/2015)... ... , ... On July 22nd the Bradenton Herald reported the Opioid ... controlling the heroin outbreak. Ultimately the committee expressed lack of funding, and the absence ... crisis in North Florida. The task force has proposed to instate counselors to meet ...
(Date:7/30/2015)... , ... July 30, 2015 , ... As more hospitals ... activity of recruiting patients becomes a serious challenge. Because of growing competition, it ... patients within the local community. , The team at Wound Care Advantage ...
(Date:7/30/2015)... ... 2015 , ... In an effort to provide the twenty four hour continuous ... in his practice. , The decision will also allow him to spend more time ... transferring his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has ...
Breaking Medicine News(10 mins):Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2
... , FRIDAY, Jan. 20 (HealthDay News) -- Rapid ... with an increased risk of asthma symptoms in preschool children, ... infancy might be a critical period for the development of ... Netherlands. They examined data collected from 5,125 children who ...
... non-intubated,patients may be an effective strategy for bridging patients ... Germany. "As waiting times for donor organs continue ... for patients with end-stage lung disease awaiting transplantation," said ... Hannover Medical School in Hannover, Germany. "Our study shows ...
... Shortages of key drugs used to fight infections represent ... risk, according to a review published in Clinical ... anti-infective shortages can substantially alter clinical care and may ... development of new anti-infectives has slowed and the prevalence ...
... , THURSDAY, Jan. 19 (HealthDay News) -- Allowing homeless ... were provided with housing actually decreased their heavy drinking by ... found. The study, published in the Jan. 19 issue ... included residents of a program called project-based Housing First, which ...
... aggressive and spread they are the most deadly. Unfortunately, ... A new imaging platform developed by Lawson Health Research ... insight into just that - the exact moment when ... E-cadherin, are important for the maintenance of normal tissue ...
... With a growing need for family-friendly workplace policies, ... Women & Families, with support from the Rockefeller Foundation, ... to positive economic outcomes for working families, businesses and ... for Women and Work at Rutgers, the State University ...
Cached Medicine News:Health News:Rapid Infant Growth Linked to Asthma in Study 2Health News:Extracorporeal membrane oxygenation as a bridge to lung transplantation 2Health News:Anti-infective drug shortages pose threat to public health and patient care 2Health News:Alcohol OK in Housing for Formerly Homeless, Study Says 2Health News:Lawson researchers engineer a switch to tame aggressive cancers 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: